Volume | 196,931 |
|
|||||
News | (1) | ||||||
Day High | 8.24 | Low High |
|||||
Day Low | 7.20 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
IGM Biosciences Inc | IGMS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
7.94 | 7.20 | 8.24 | 7.28 | 7.94 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,292 | 196,931 | US$ 7.51 | US$ 1,479,391 | - | 3.81 - 17.70 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:23:48 | 9 | US$ 7.29 | USD |
IGM Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
429.73M | 58.79M | - | 2.13M | -246.42M | -4.19 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
IGM Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IGMS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.20 | 8.50 | 7.15 | 7.94 | 282,137 | -0.92 | -11.22% |
1 Month | 9.36 | 12.31 | 7.15 | 9.58 | 452,189 | -2.08 | -22.22% |
3 Months | 10.28 | 12.31 | 6.39 | 9.18 | 329,239 | -3.00 | -29.18% |
6 Months | 6.42 | 17.70 | 5.90 | 10.30 | 317,054 | 0.86 | 13.40% |
1 Year | 10.38 | 17.70 | 3.81 | 8.76 | 315,593 | -3.10 | -29.87% |
3 Years | 92.16 | 96.11 | 3.81 | 21.58 | 336,450 | -84.88 | -92.10% |
5 Years | 18.31 | 133.00 | 3.81 | 31.62 | 274,724 | -11.03 | -60.24% |
IGM Biosciences Description
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. |